Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
40
BBLG Quote, Financials, Valuation and Earnings
Last price:
$2.01
Seasonality move
:
-35.57%
Day range:
$1.92 - $2.03
52-week range:
$1.30 - $7.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.18x
Volume:
18.9K
Avg. volume:
37.9K
1-year change:
-70.37%
Market cap:
$1.1M
Revenue:
--
EPS (TTM):
-$6.71
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Bone Biologics Corp. has 997.68% upside to fair value with a price target of $22.25 per share.
BBLG vs. S&P 500
-
Over the past 5 trading days, Bone Biologics Corp. has overperformed the S&P 500 by 5.69% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bone Biologics Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bone Biologics Corp. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Bone Biologics Corp. reported revenues of --.
Earnings Growth
-
Bone Biologics Corp. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Bone Biologics Corp. reported earnings per share of -$0.37.
Enterprise value:
-4.9M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
1.48x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-80.72%
Net Income Margin (TTM):
--
Return On Equity:
-86.54%
Return On Invested Capital:
-86.54%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$9.6M | -$3.8M | -$4.1M | -$951K | -$715.3K | |
| EBITDA | -$9.6M | -$3.8M | -$4.1M | -$951K | -$715.3K | |
| Diluted EPS | -$59.65 | -$5.42 | -$6.71 | -$0.54 | -$0.37 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $52.4K | $5.2M | $5M | $4.1M | $6.4M | |
| Total Assets | $52.4K | $5.2M | $5M | $4.1M | $6.4M | |
| Current Liabilities | $15.2M | $799.5K | $1.2M | $273.4K | $334.3K | |
| Total Liabilities | $15.2M | $799.5K | $1.2M | $273.4K | $334.3K | |
| Total Equity | -$15.1M | $4.4M | $3.8M | $3.8M | $6M | |
| Total Debt | $12.1M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$9.5M | -$4.8M | -$3.3M | -$572.2K | -$591.4K | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $8.9M | $3.9M | $5.8M | $1.8M | -- | |
| Free Cash Flow | -$9.5M | -$4.8M | -$3.3M | -$572.2K | -$591.4K | |
BBLG
Sector
Market Cap
$1.1M
$28.7M
Price % of 52-Week High
26.19%
52.89%
Dividend Yield
0%
0%
Shareholder Yield
-382.12%
-1.4%
1-Year Price Total Return
-70.37%
-19%
Beta (5-Year)
0.519
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.94
200-day SMA
Sell
Level
$3.33
Bollinger Bands (100)
Sell
Level
1.8 - 2.58
Chaikin Money Flow
Sell
Level
-94.8M
20-day SMA
Buy
Level
$1.67
Relative Strength Index (RSI14)
Buy
Level
58.69
ADX Line
Buy
Level
26.32
Williams %R
Sell
Level
-16.0241
50-day SMA
Buy
Level
$2.02
MACD (12, 26)
Buy
Level
0.03
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
195.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-28.9366)
Sell
CA Score
(Annual)
Level (-3.9066)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (22.3192)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bone Biologics Corp. operates as a medical device company. engages in the research and development of bone regeneration in spinal fusion. Its product is Nell-1, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. Its platform technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company was founded by Eric Kang Ting, Chia Soo and Benjamin Wu in 2004 and is headquartered in Burlington, MA.
Stock Forecast FAQ
In the current month, BBLG has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BBLG average analyst price target in the past 3 months is $22.25.
-
Where Will Bone Biologics Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bone Biologics Corp. share price will rise to $22.25 per share over the next 12 months.
-
What Do Analysts Say About Bone Biologics Corp.?
Analysts are divided on their view about Bone Biologics Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bone Biologics Corp. is a Sell and believe this share price will drop from its current level to $22.25.
-
What Is Bone Biologics Corp.'s Price Target?
The price target for Bone Biologics Corp. over the next 1-year time period is forecast to be $22.25 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BBLG A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bone Biologics Corp. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BBLG?
You can purchase shares of Bone Biologics Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bone Biologics Corp. shares.
-
What Is The Bone Biologics Corp. Share Price Today?
Bone Biologics Corp. was last trading at $2.01 per share. This represents the most recent stock quote for Bone Biologics Corp.. Yesterday, Bone Biologics Corp. closed at $2.03 per share.
-
How To Buy Bone Biologics Corp. Stock Online?
In order to purchase Bone Biologics Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BBLG Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BBLG
Sector
P/E ratio
--
24.19x
PEG ratio
-0.01x
-0.01x
P/B ratio
0.18x
1.84x
Price / LTM sales
--
1.61x
Growth Metrics
BBLG
Sector
Revenue growth
--
4.6%
Earnings growth
30.8%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$1.23
-$0.20
Profitability
BBLG
Sector
Profitability FY 2024
--
$3.5M
Return on invested capital
-86.54%
-31.61%
Return on assets
-80.72%
-27.83%
Return on equity
-86.54%
-37.15%
Earnings Date
Last Earnings Date
Dec
14
Next Earnings Date
Dec
14
Estimated Next Earnings Date
Mar
15
Balance Sheet
BBLG
Sector
Total cash
$6M
$26.8M
Short term investments
--
$26M
Total assets
$3.9M
$79.7M
Long term debt
--
$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 13
Frequency Electronics, Inc. [FEIM] is up 28.76% over the past day.
Buy
57
MOD alert for Dec 13
Modine Manufacturing Co. [MOD] is down 15.32% over the past day.
Sell
42
OKLO alert for Dec 13
Oklo, Inc. [OKLO] is down 14.91% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
